期刊
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
卷 16, 期 5, 页码 E321-E331出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ijid.2012.01.003
关键词
Influenza, human; Pneumonia, bacterial; Antiviral agents; Influenza A virus; Antibacterial agents
资金
- Wyeth
- Pfizer Inc.
- Pfizer
- Astellas
- AstraZeneca
- Cempra
- Cerexa/Forest
- Medicines Company
- Boehringer Ingelheim
- Gilead
- Tibotec
- GlaxoSmithKline
Post-influenza bacterial pneumonia is a major cause of morbidity and mortality associated with both seasonal and pandemic influenza virus illness. However, despite much interest in influenza and its complications in recent years, good clinical trial data to inform clinicians in their assessment of treatment options are scant. This paucity of evidence needs to be addressed urgently in order to improve guidance on the management of post-influenza bacterial pneumonia. The objectives of the current article are to evaluate the emergence of the 2009 H1N1 influenza pandemic and use this information as background for an in-depth review of the epidemiology of bacterial pneumonia complicating influenza, to review the bacterial pathogens most likely to be associated with post-influenza bacterial pneumonia, and to discuss treatment considerations in these patients. When determining optimal management approaches, both antiviral and antibacterial agents should be considered, and their selection should be based upon a clear understanding of how their mechanisms of action intervene in the pathogenesis of post-influenza acute bacterial pneumonia. (C) 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据